We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

dinsdag 25 juli 2017

The Lancet: [Comment] Progress on dementia—leaving no one behind

[Comment] Progress on dementia—leaving no one behind
The Lancet Commission Dementia Prevention, Intervention, and Care1 makes a timely evidence-driven contribution to global efforts to improve the lives of people with dementia and their carers, and limit the future impact on societies. The Commission proposes ambitious prevention targets, treatment of cognitive symptoms in people with Alzheimer's disease or dementia with Lewy bodies, individualised dementia care, provision of care for carers, planning for the future for patients and families, risk protection balanced with respect for autonomy, management of neuropsychiatric symptoms, consideration of dementia in end of life care, and use of technological innovations to improve care but not replace social contact.
Read more

[Articles] Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
The two-drug combination of all-injectable, long-acting cabotegravir plus rilpivirine every 4 weeks or every 8 weeks was as effective as daily three-drug oral therapy at maintaining HIV-1 viral suppression through 96 weeks and was well accepted and tolerated.
Read more

[Comment] Long-acting injectable ART: next revolution in HIV?
In the two decades since the arrival of triple antiretroviral therapy (ART),1,2 there have been multiple breakthroughs including new drugs in new classes, simplification from complex, restrictive regimens to single fixed-dose multiclass tablets, and major improvements in tolerability and toxicity.3–5 There is even an emerging re-examination of the triple therapy paradigm itself. Studies have shown that some dual-therapy combinations appear to confer the same success as conventional triple regimens, whether in individuals who are naive to ART or as a switch strategy.
Read more

[Comment] Is there a future for mRNAs as viral vaccines?
The first trial of an mRNA vaccine in human beings against an infectious disease is reported by Martin Alberer and colleagues1 in The Lancet. Similar mRNA vaccines have been found to induce some immunity against tumour antigens when tested in patients with melanoma or prostate cancer.2,3
Read more

[Viewpoint] The French emergency medical services after the Paris and Nice terrorist attacks: what have we learnt?
On Nov 13, 2015, Paris was the scene of multiple mass casualty terrorist attacks that were the most violent and devastating events to occur in France since World War 2, resulting in the deaths of 137 people and injuring 413.1 On July 14, 2016, France was targeted again in the attack on Nice in which a truck was deliberately driven into crowds celebrating Bastille Day, resulting in the deaths of 87 people and injuring 458. Since the attack on Nice, several further terrorist attacks have occurred in Europe (figure),3 providing the sad proof that the threat has spread to many countries.
Read more